Patch Testing During the COVID-19 Pandemic : Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)
Copyright © 2020. Publicado por Elsevier España, S.L.U..
As the COVID-19 pandemic gradually comes under control, the members of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) have drawn up a proposed list of the requirements, limitations, and conditioning factors affecting the resumption of work in contact dermatitis units. The assumption is that the severe acute respiratory syndrome coronavirus2 is still circulating and that occasional or seasonal outbreaks will occur. They recommend that the first step should be to assess how many patch tests each clinic can handle and review the waiting list to prioritize cases according to disease severity and urgency. Digital technologies can, where possible, be used to send and receive the documentation necessary for the patch test (information, instructions, informed consent, etc.). If the necessary infrastructure is available, patients can be offered the option of a remote initial consultation. Likewise, in selected cases, the patch test results can be read in a virtual visit using photographs taken by the patient or a video visit can be scheduled to allow the physician to evaluate the site of application remotely. These measures will reduce the number of face-to-face visits required, but will not affect the time spent on each case, which must be scheduled in the normal manner. All of these recommendations are suggestions and should be adapted to the needs and possibilities of each health centre.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Actas dermo-sifiliograficas - 111(2020), 8 vom: 01. Okt., Seite 650-654 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Recomendaciones del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) de la AEDV en relación con la realización de pruebas epicutáneas durante la pandemia por SARS-CoV-2 (COVID-19) |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.10.2020 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ad.2020.06.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312005911 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312005911 | ||
| 003 | DE-627 | ||
| 005 | 20231225143457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ad.2020.06.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM312005911 | ||
| 035 | |a (NLM)32622869 | ||
| 035 | |a (PII)S0001-7310(20)30221-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrascosa, J M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patch Testing During the COVID-19 Pandemic |b Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) |
| 246 | 3 | 3 | |a Recomendaciones del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) de la AEDV en relación con la realización de pruebas epicutáneas durante la pandemia por SARS-CoV-2 (COVID-19) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2020 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Publicado por Elsevier España, S.L.U. | ||
| 520 | |a As the COVID-19 pandemic gradually comes under control, the members of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) have drawn up a proposed list of the requirements, limitations, and conditioning factors affecting the resumption of work in contact dermatitis units. The assumption is that the severe acute respiratory syndrome coronavirus2 is still circulating and that occasional or seasonal outbreaks will occur. They recommend that the first step should be to assess how many patch tests each clinic can handle and review the waiting list to prioritize cases according to disease severity and urgency. Digital technologies can, where possible, be used to send and receive the documentation necessary for the patch test (information, instructions, informed consent, etc.). If the necessary infrastructure is available, patients can be offered the option of a remote initial consultation. Likewise, in selected cases, the patch test results can be read in a virtual visit using photographs taken by the patient or a video visit can be scheduled to allow the physician to evaluate the site of application remotely. These measures will reduce the number of face-to-face visits required, but will not affect the time spent on each case, which must be scheduled in the normal manner. All of these recommendations are suggestions and should be adapted to the needs and possibilities of each health centre | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Contact | |
| 650 | 4 | |a Contacto | |
| 650 | 4 | |a Dermatitis | |
| 650 | 4 | |a Epicutáneas | |
| 650 | 4 | |a Patch testing | |
| 650 | 4 | |a Telemedicina | |
| 650 | 4 | |a Telemedicine | |
| 700 | 1 | |a Pastor-Nieto, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-González, I |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestre, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Borrego, L |e verfasserin |4 aut | |
| 700 | 1 | |a Gatica-Ortega, M E |e verfasserin |4 aut | |
| 700 | 1 | |a Giménez-Arnau, A M |e verfasserin |4 aut | |
| 700 | 0 | |a en representación del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) |e verfasserin |4 aut | |
| 700 | 0 | |a Miembros del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) |e verfasserin |4 aut | |
| 700 | 1 | |a Armario Hita, José Carlos |e investigator |4 oth | |
| 700 | 1 | |a Borrego Hernando, Leopoldo |e investigator |4 oth | |
| 700 | 1 | |a Carrascosa Carrillo, José Manuel |e investigator |4 oth | |
| 700 | 1 | |a Córdoba Guijarro, Susana |e investigator |4 oth | |
| 700 | 1 | |a Curto, Laia |e investigator |4 oth | |
| 700 | 1 | |a Fernández Redondo, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Figueras Nart, Ignasi |e investigator |4 oth | |
| 700 | 1 | |a García Gavín, Juan |e investigator |4 oth | |
| 700 | 1 | |a Elena Gatica Ortega, María |e investigator |4 oth | |
| 700 | 1 | |a Giménez Arnau, Anna |e investigator |4 oth | |
| 700 | 1 | |a Giménez Arnau, Elena |e investigator |4 oth | |
| 700 | 1 | |a Gómez de la Fuente, Enrique |e investigator |4 oth | |
| 700 | 1 | |a González Pérez, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Heras Mendaza, Felipe |e investigator |4 oth | |
| 700 | 1 | |a Hervella Garcés, Marcos |e investigator |4 oth | |
| 700 | 1 | |a Manrique Martínez, Pilar |e investigator |4 oth | |
| 700 | 1 | |a Mercader García, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Javier Ortiz de Frutos, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Miquel Miquel, Javier |e investigator |4 oth | |
| 700 | 1 | |a Antonia Pastor Nieto, María |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez Serna, Mercedes |e investigator |4 oth | |
| 700 | 1 | |a Ruíz González, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a Sánchez Gilo, Araceli |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Pedreño Guillén, Paloma |e investigator |4 oth | |
| 700 | 1 | |a Sánchez Pérez, Javier |e investigator |4 oth | |
| 700 | 1 | |a Sanz Sánchez, Tatiana |e investigator |4 oth | |
| 700 | 1 | |a Serra-Baldrich, Esther |e investigator |4 oth | |
| 700 | 1 | |a Silvestre Salvador, Juan Francisco |e investigator |4 oth | |
| 700 | 1 | |a Zaragoza Ninet, Violeta |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Actas dermo-sifiliograficas |d 2011 |g 111(2020), 8 vom: 01. Okt., Seite 650-654 |w (DE-627)NLM205627536 |x 2173-5778 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2020 |g number:8 |g day:01 |g month:10 |g pages:650-654 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ad.2020.06.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2020 |e 8 |b 01 |c 10 |h 650-654 | ||